Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback